Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)

Summary

The standard treatment choice for advanced hepatocellular carcinoma (HCC) is sorafenib, and its efficacy is limited. More active treatments were performed in patients with advanced HCC in China, which include radical hepatectomy or TACE. The study is to investigate whether the active treatment will profit survival of patients, and to evaluate the safety.

Timeline

Start

2011-01

Primary completion

2017-06

Completion

2018-01

Drugs

Indications